Del Medico Zajac María Paula, Zanetti Flavia Adriana, Esusy María Soledad, Federico Carlos Rodolfo, Zabal Osvaldo, Valera Alejandro Rafael, Calamante Gabriela
1 Instituto de Biotecnología, Instituto Nacional de Tecnología Agropecuaria (CICVyA-INTA) , Hurlingham, Argentina .
2 Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) , Ciudad Autónoma de Buenos Aires, Argentina .
Viral Immunol. 2017 Jan/Feb;30(1):70-76. doi: 10.1089/vim.2016.0090. Epub 2016 Nov 3.
In this study, we evaluated the immunogenicity and efficacy of mucosal delivery of a recombinant modified vaccinia Ankara virus (MVA) expressing the secreted version of bovine herpesvirus type 1 (BoHV-1) glycoprotein D (MVA-gDs) without addition of adjuvant in two animal models. First, we demonstrated the capability of MVA-gDs of inducing both local and systemic anti-gD humoral immune response after intranasal immunization of mice. Then, we confirmed that two doses of MVA-gDs administered intranasally to rabbits induced systemic anti-gD antibodies and conferred protection against BoHV-1 challenge. Our results show the potential of using MVA as a vector for the rational design of veterinary vaccines capable of inducing specific and protective immune responses both at local and systemic level.
在本研究中,我们在两种动物模型中评估了无佐剂情况下黏膜递送表达牛疱疹病毒1型(BoHV-1)糖蛋白D分泌形式的重组改良安卡拉痘苗病毒(MVA)(MVA-gDs)的免疫原性和效力。首先,我们证明了小鼠经鼻免疫后,MVA-gDs能够诱导局部和全身抗gD体液免疫反应。然后,我们证实给兔子经鼻接种两剂MVA-gDs可诱导全身抗gD抗体,并提供针对BoHV-1攻击的保护。我们的结果显示了使用MVA作为载体合理设计兽用疫苗的潜力,这种疫苗能够在局部和全身水平诱导特异性和保护性免疫反应。